Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma, a biopharmaceutical company specializing in drug development, has reported a successful quarter with revenue matching the quarterly average and a strategic expansion into the US market via the OTCQB Venture Market. The company appointed a new CFO with extensive financial leadership experience and raised significant capital through placements, which will support its drug development pipeline. This includes the development of treatments for CNS and Immunology that will be available in the US and EU markets.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
